BRAIN and NERVE－神経研究の進歩71巻9号

2019年09月発行

特集 神経疾患のドラッグ・リポジショニング—新時代へ

アルツハイマー病のドラッグ・リポジショニング

著者： 猪原匡史¹ 齊藤聡¹

所属機関： ¹国立研究開発法人国立循環器病研究センター脳神経内科

ページ範囲：P.961 - P.970

文献概要

アルツハイマー病（AD）の多くの疾患修飾薬開発が失敗に終わり，その新薬開発は大きな転換点を迎えている。ドラッグ・リポジショニング（DR）の手法を用いれどもADの創薬には多くの困難を伴うが，少なくともより安価で確実性の高い開発が可能となる。現在世界中で進行中のADを対象とした治験の約4割がDRの手法を用いており，現状を打破するAD創薬の起爆剤となることが期待されている。

参考文献

1)Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, et al: How to improve R＆D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 9: 203-214, 2010［doi: 10.1038/nrd3078］

2)森　和彦: これからのDDS学会への提言（行政の立場から）. Drug Deliv Syst 29: 73-76, 2014

3)井上和秀: エコファーマという創薬技術　ドラッグリポジショニングとの相違. 実験医学32: 259-265, 2014

4)Thayer AM: Drug repurposing. Chem ＆ Engineering News 90: 15-25, 2012

5)de Castro AA, da Cunha EFF, Pereira AF, Soares FV, Leal DHS, et al: Insights into the drug repositioning applied to the Alzheimer's disease treatment and future perspectives. Curr Alzheimer Res 15: 1161-1178, 2018［doi: 10.2174/1567205015666180813150703］

6)齊藤　聡, 山本由美, 猪原匡史: ドラッグ・リポジショニングの新展開. 日本老年医学会雑誌52: 200-205, 2015

7)Schneider JA, Arvanitakis Z, Bang W, Bennett DA: Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 69: 2197-2204, 2007［doi: 01.wnl.0000271090.28148.24］

8)Saito S, Ihara M: New therapeutic approaches for Alzheimer's disease and cerebral amyloid angiopathy. Front Aging Neurosci 6: 290, 2014［doi: 10.3389/fnagi.2014.00290］

9)Kokjohn TA, Roher AE: Amyloid precursor protein transgenic mouse models and Alzheimer's disease: understanding the paradigms, limitations, and contributions. Alzheimers Dement 5: 340-347, 2009

10)Shineman DW, Alam J, Anderson M, Black SE, Carman AJ, et al: Overcoming obstacles to repurposing for neurodegenerative disease. Ann Clin Transl Neurol 1: 512-518, 2014

11)Gaudry KS: Evergreening: a common practice to protect new drugs. Nat Biotechnol 29: 876-878, 2011

12)水島　徹: なぜ今DRなのか　創薬の新しい流れ. 実験医学32: 2277-2281, 2014

13)Cummings J, Lee G, Ritter A, Zhong K: Alzheimer's disease drug development pipeline: 2018. Alzheimers Dement (N Y) 4: 195-214, 2018

14)Saito S, Yamamoto Y, Ihara M: Development of a multicomponent intervention to prevent Alzheimer's disease. Front Neurol 10: 490, 2019［doi.org/10.3389/fneur.2019.00490］

15)Adlard PA, Bush AI: Metals and Alzheimer's disease: how far have we come in the clinic? J Alzheimers Dis 62: 1369-1379, 2018

16)Maki T, Okamoto Y, Carare RO, Hase Y, Hattori Y, et al: Phosphodiesterase III inhibitor promotes drainage of cerebrovascular β-amyloid. Ann Clin Transl Neurol 1: 519-533, 2014

17)Medina M: An overview on the clinical development of tau-based therapeutics. Int J Mol Sci 19: E1160, 2018［doi: 10.3390/ijms19041160］

18)Braidy N, Berg J, Clement J, Khorshidi F, Poljak A, et al: Role of nicotinamide adenine dinucleotide and related precursors as therapeutic targets for age-related degenerative diseases: Rationale, Biochemistry, Pharmacokinetics, and Outcomes. Antioxid Redox Signal 30: 251, 2018［doi: 10.1089/ars.2017.7269］

19)McGeer PL, Rogers J, McGeer EG: Inflammation, antiinflammatory agents, and Alzheimer's disease: the last 22 years. J Alzheimers Dis 54: 853-857, 2016

20)Rahman SO, Singh RK, Hussain S, Akhtar M, Najmi AK: A novel therapeutic potential of cysteinyl leukotrienes and their receptors modulation in the neurological complications associated with Alzheimer's disease. Eur J Pharmacol 842: 208-220, 2019

21)Zhang C, Griciuc A, Hudry E, Wan Y, Quinti L, et al: Cromolyn reduces levels of the Alzheimer's disease-associated amyloid β-protein by promoting microglial phagocytosis. Sci Rep 8: 1144, 2018［doi: 10.1038/s41598-018-19641-2］

22)Haas JG, Lathe R: Microbes and Alzheimer's disease: new findings call for a paradigm change. Trends Neurosci 41: 570-573, 2018

23)de la Monte SM, Wands JR: Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol 2: 1101-1113, 2008

24)Gudala K, Bansal D, Schifano F, Bhansali A: Diabetes mellitus and risk of dementia: a meta-analysis of prospective observational studies. J Diabetes Investig 4: 640-650, 2013

25)Agrawal M, Saraf S, Saraf S, Antimisiaris SG, Chougule MB et al: Nose-to-brain drug delivery: an update on clinical challenges and progress towards approval of anti-Alzheimer drugs. J Control Release 281: 139-177, 2018

26)Femminella GD, Frangou E, Love SB, Busza G, Holmes C, et al: Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study). Trials 20: 191, 2019［doi: 10.1186/s13063-019-3259-x］

27)Ajith TA: A recent update on the effects of omega-3 fatty acids in Alzheimer's disease. Curr Clin Pharmacol 13: 252-260, 2018

28)Iturria-Medina Y, Sotero RC, Toussaint PJ, Mateos-Pérez JM, Evans AC, et al: Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis. Nat Commun 7: 11934, 2016

29)Saito S, Ihara M: New therapeutic approaches for Alzheimer's disease and cerebral amyloid angiopathy. Front Aging Neurosci 6: 290, 2014［doi: 10.3389/fnagi.2014.00290］

30)Saito S, Kojima S, Oishi N, Kakuta R, Maki T, et al: A multicenter, randomized, placebo-controlled trial for cilostazol in patients with mild cognitive impairment: the COMCID study protocol. Alzheimers Dement (N Y) 2: 250-257, 2016